Loading...
XNAS
KURA
Market cap515mUSD
Aug 07, Last price  
5.96USD
1D
-1.16%
1Q
3.47%
Jan 2017
1.02%
IPO
-26.15%
Name

Kura Oncology Inc

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
9.58
EPS
—
Div Yield, %
—
Shrs. gr., 5y
15.48%
Rev. gr., 5y
%
Revenues
54m
000000000000000053,883,000
Net income
-174m
L+13.99%
-33,623-19,996-22,395-22,395-27,040-27,315-11,013,000-22,625,000-27,560,000-35,434,000-60,447,000-63,140,000-89,431,000-129,908,000-136,069,000-152,631,000-173,983,000
CFO
134m
P
-31,765-21,366-19,244-19,244-22,678-24,418-2,547-17,925,000-25,349,000-28,441,000-48,655,000-54,760,000-69,830,000-104,551,000-110,062,000-124,824,000134,317,000

Profile

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
URL
https://www.kuraoncology.com/
IPO date
Nov 05, 2015
Employees
133
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
53,883
 
Cost of revenue
247,078
166,653
140,624
Unusual Expense (Income)
NOPBT
(193,195)
(166,653)
(140,624)
NOPBT Margin
Operating Taxes
2,018
229
Tax Rate
NOPAT
(195,213)
(166,653)
(140,853)
Net income
(173,983)
13.99%
(152,631)
12.17%
(136,069)
4.74%
Dividends
Dividend yield
Proceeds from repurchase of equity
145,813
93,577
24,721
BB yield
-19.43%
-8.89%
-2.97%
Debt
Debt current
6,369
3,012
2,318
Long-term debt
19,177
23,562
16,572
Deferred revenue
Other long-term liabilities
255,701
705
265
Net debt
(701,849)
(397,383)
(419,305)
Cash flow
Cash from operating activities
134,317
(124,824)
(110,062)
CAPEX
(472)
(168)
(626)
Cash from investing activities
(101,590)
15,557
32,627
Cash from financing activities
154,417
94,783
38,565
FCF
(193,846)
(169,123)
(138,989)
Balance
Cash
727,395
423,957
437,985
Long term investments
210
Excess cash
724,701
423,957
438,195
Stockholders' equity
(894,650)
(722,703)
(576,833)
Invested Capital
1,582,466
1,139,387
22,314
ROIC
ROCE
EV
Common stock shares outstanding
86,161
73,229
66,990
Price
8.71
-39.43%
14.38
15.87%
12.41
-11.36%
Market cap
750,462
-28.73%
1,053,033
26.67%
831,346
-10.50%
EV
48,613
655,650
412,041
EBITDA
(192,347)
(165,804)
(139,865)
EV/EBITDA
Interest
1,619
1,549
229
Interest/NOPBT